Literature DB >> 27308580

P2RX7: A receptor with a split personality in inflammation and cancer.

Francesco Di Virgilio1.   

Abstract

P2X7 (also known as P2RX7) is a plasma membrane receptor for extracellular ATP that is expressed at a high level by immune and tumor cells. Previous data showed that increased P2rx7 expression by tumor cells accelerates tumor progression. We have now looked at the other side of the relationship by investigating the effect of a lack of host P2rx7 expression on tumor growth. Our novel observations highlight a surprising role of host P2rx7 in restraining tumor progression.

Entities:  

Keywords:  extracellular ATP; immunity; purinergic receptors; tumors

Year:  2015        PMID： 27308580      PMCID： PMC4905332          DOI： 10.1080/23723556.2015.1010937

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Dr. Jekyll/Mr. Hyde: the dual role of extracellular ATP.

Authors:  F Di Virgilio
Journal:  J Auton Nerv Syst       Date:  2000-07-03

2.  P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness.

Authors:  B Jelassi; A Chantôme; F Alcaraz-Pérez; A Baroja-Mazo; M L Cayuela; P Pelegrin; A Surprenant; S Roger
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

3.  Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer.

Authors:  Paul Hofman; Julien Cherfils-Vicini; Marie Bazin; Marius Ilie; Thierry Juhel; Xavier Hébuterne; Eric Gilson; Annie Schmid-Alliana; Olivier Boyer; Sahil Adriouch; Valérie Vouret-Craviari
Journal:  Cancer Res       Date:  2015-01-06       Impact factor: 12.701

4.  Responses of mouse lymphocytes to extracellular adenosine 5'-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP.

Authors:  F Di Virgilio; V Bronte; D Collavo; P Zanovello
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

5.  Expression of P2X7 receptor increases in vivo tumor growth.

Authors:  Elena Adinolfi; Lizzia Raffaghello; Anna Lisa Giuliani; Luigi Cavazzini; Marina Capece; Paola Chiozzi; Giovanna Bianchi; Guido Kroemer; Vito Pistoia; Francesco Di Virgilio
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

6.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Authors:  Konrad Wilhelm; Jayanthi Ganesan; Tobias Müller; Christoph Dürr; Melanie Grimm; Andreas Beilhack; Christine D Krempl; Stephan Sorichter; Ulrike V Gerlach; Eva Jüttner; Alf Zerweck; Frank Gärtner; Patrizia Pellegatti; Francesco Di Virgilio; Davide Ferrari; Neeraja Kambham; Paul Fisch; Jürgen Finke; Marco Idzko; Robert Zeiser
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

7.  Accelerated tumor progression in mice lacking the ATP receptor P2X7.

Authors:  Elena Adinolfi; Marina Capece; Alessia Franceschini; Simonetta Falzoni; Anna L Giuliani; Alessandra Rotondo; Alba C Sarti; Massimo Bonora; Susanne Syberg; Domenica Corigliano; Paolo Pinton; Niklas R Jorgensen; Luigi Abelli; Laura Emionite; Lizzia Raffaghello; Vito Pistoia; Francesco Di Virgilio
Journal:  Cancer Res       Date:  2014-12-26       Impact factor: 12.701

8.  ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.

Authors:  G Bianchi; M Vuerich; P Pellegatti; D Marimpietri; L Emionite; I Marigo; V Bronte; F Di Virgilio; V Pistoia; L Raffaghello
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

Review 9.  Purinergic signalling: from discovery to current developments.

Authors:  Geoffrey Burnstock
Journal:  Exp Physiol       Date:  2013-09-27       Impact factor: 2.969

Review 10.  Purines, purinergic receptors, and cancer.

Authors:  Francesco Di Virgilio
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701
  10 in total
  10 in total

1.  Modulation of the TGF-β1-induced epithelial to mesenchymal transition (EMT) mediated by P1 and P2 purine receptors in MDCK cells.

Authors:  Mariachiara Zuccarini; Patricia Giuliani; Silvana Buccella; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Marzia Carluccio; Margherita Rossini; Daniele Filippo Condorelli; Michel Piers Rathbone; Francesco Caciagli; Renata Ciccarelli; Patrizia Di Iorio
Journal:  Purinergic Signal       Date:  2017-06-14       Impact factor: 3.765

Review 2.  Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.

Authors:  Paola de Andrade Mello; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio
Journal:  Front Immunol       Date:  2017-11-14       Impact factor: 7.561

Review 3.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Authors:  Luiz E B Savio; Paola de Andrade Mello; Cleide Gonçalves da Silva; Robson Coutinho-Silva
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

Review 4.  Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.

Authors:  Roger Gilabert-Oriol; Gemma M Ryan; Ada W Y Leung; Natalie S Firmino; Kevin L Bennewith; Marcel B Bally
Journal:  Int J Mol Sci       Date:  2018-09-26       Impact factor: 5.923

5.  A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy.

Authors:  Laetitia Douguet; Serena Janho Dit Hreich; Jonathan Benzaquen; Laetitia Seguin; Thierry Juhel; Xavier Dezitter; Christophe Duranton; Bernhard Ryffel; Jean Kanellopoulos; Cecile Delarasse; Nicolas Renault; Christophe Furman; Germain Homerin; Chloé Féral; Julien Cherfils-Vicini; Régis Millet; Sahil Adriouch; Alina Ghinet; Paul Hofman; Valérie Vouret-Craviari
Journal:  Nat Commun       Date:  2021-01-28       Impact factor: 14.919

Review 6.  Purinergic signaling in peripheral nervous system glial cells.

Authors:  Jennifer Patritti-Cram; Robert A Coover; Michael P Jankowski; Nancy Ratner
Journal:  Glia       Date:  2021-01-28       Impact factor: 7.452

7.  A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Authors:  Julie Le Naour; Zsofia Sztupinszki; Vincent Carbonnier; Odile Casiraghi; Virginie Marty; Lorenzo Galluzzi; Zoltan Szallasi; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2022-04-17       Impact factor: 7.723

8.  Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.

Authors:  Rasha Al-Khalidi; Chiara Panicucci; Paul Cox; Natalia Chira; Justyna Róg; Christopher N J Young; Rhiannon E McGeehan; Kameshwari Ambati; Jayakrishna Ambati; Krzysztof Zabłocki; Elisabetta Gazzerro; Stephen Arkle; Claudio Bruno; Dariusz C Górecki
Journal:  Acta Neuropathol Commun       Date:  2018-04-11       Impact factor: 7.801

Review 9.  P2RX7 Purinoceptor as a Therapeutic Target-The Second Coming?

Authors:  Chris N J Young; Dariusz C Górecki
Journal:  Front Chem       Date:  2018-06-28       Impact factor: 5.221

10.  Human P2X7 Receptor Causes Cycle Arrest in RPMI-8226 Myeloma Cells to Alter the Interaction with Osteoblasts and Osteoclasts.

Authors:  Ankita Agrawal; Lars S Kruse; Annette J Vangsted; Alison Gartland; Niklas R Jørgensen
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.